Table 3.

Association between covid-19 vaccination or SARS-CoV-2 infection and occurrence of immune mediated neurological disorders of special interest in UK’s Clinical Practice Research Datalink AURUM database

Event by vaccine and dose	No of participants	Person years	Observed events	Expected events	Standardised incidence ratio (95% CI)
Bell’s palsy
ChAdOx1 nCoV-19:
First dose	3 776 803	384 250	117	164.5	0.71 (0.59 to 0.85)
Second dose	1 093 258	218 629	25	94.7	0.26 (0.18 to 0.39)
BNT162b2:
First dose	1 693 453	275 333	46	116.4	0.40 (0.30 to 0.53)
Second dose	1 166 571	235 351	24	99.5	0.24 (0.16 to 0.36)
SARS-CoV-2 positive test result	446 851	106 342	53	39.8	1.33 (1.02 to 1.74)
Encephalomyelitis
ChAdOx1 nCoV-19:
First dose	3 778 358	384 420	11	7.6	1.45 (0.80 to 2.62)
BNT162b2:
First dose	1 694 161	275 451	<5	5.4
Second dose	1 167 028	235 447	<5	4.6
SARS-CoV-2 positive test result	447 037	106 391	11	1.6	6.89 (3.82 to 12.44)
Guillain-Barré syndrome
ChAdOx1 nCoV-19:
First dose	3 778 430	384 427	11	14.9	0.74 (0.41 to 1.33)
Second dose	1 093 778	218 737	<5	9.5
BNT162b2:
First dose	1 694 167	275 452	<5	10.4
Second dose	1 167 031	235 448	<5	9.0
SARS-CoV-2 positive test result	447 029	106 390	9	2.6	3.53 (1.83 to 6.77)
Transverse myelitis
ChAdOx1 nCoV-19:
First dose	3 778 434	384 430	<5	7.6
BNT162b2:
First dose	1 694 190	275 456	<5	4.7
SARS-CoV-2 positive test result	447 041	106 393	<5	1.9

Events with fewer than five occurrences have been omitted for privacy reasons. No events were observed for omitted cohorts.